Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma : vimarsana.com

Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

Investegate announcements from Sanofi - Aventis Groupe, New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

Related Keywords

Japan , Tennessee , United States , Paris , France General , France , Vanderbilt University , Eva Schaefer Jansen , Arnaud Delepine , Felix Lauscher , Sharon Chen , Leonardb Bacharier , Vesna Tosic , Monroe Carell Jr , Nathalie Pham , Sally Bain , Pediatric Asthma Research , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Dupilumab Development Program , Teva Pharmaceutical Industries Ltd , Exchange Commission , European Union , European Medicines Agency , Children Hospital At Vanderbilt University Medical Center , New England Journal , England Journal , Monroe Carell , Vanderbilt University Medical Center , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Investegate Announcements , Nvestegate Company Announcements , Anofi Aventis Groupe , Lobenewswire , Lobenewswire And Globenewswire , Nw ,